Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8829960 | 0.82 | — | — | |
| SCHEMBL2068001 | 0.82 | — | — | |
| SCHEMBL2067814 | 0.79 | — | — | |
| SCHEMBL5005762 | 0.79 | RIPK1 (0.30) | — | |
| SCHEMBL2066693 | 0.77 | NPSR1 (0.30) | — | |
| SCHEMBL177791 | 0.76 | HCAR2 (0.30) | — | |
| SCHEMBL1499394 | 0.76 | — | — | |
| SCHEMBL177646 | 0.76 | — | — | |
| SCHEMBL2066894 | 0.74 | — | — | |
| SCHEMBL601222 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116574135-A | Condensed ring compound, electroluminescent device and display device | 京东方科技集团股份有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-114206886-A | Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same | 广东聚华印刷显示技术有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-112480177-A | Luminescent diaza-, monoaza-and benzo-imidazole metal carbene complexes for use in electronic devices and methods for their preparation | UDC 爱尔兰有限责任公司 | 2021-03-12 | — | — | CN | claimed |
| WO-2021016814-A1 | LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2021-02-04 | — | — | WO | claimed |
| US-10290817-B2 | Luminescent diaza-monoaza-and benzimidazole metal carbene complexes for use in electronic devices such as OLEDs | UDC IRELAND LIMITED (IE) | 2019-05-14 | — | — | US | claimed |
| US-20160172606-A1 | LUMINESCENT DIAZA-MONOAZA-AND BENZIMIDAZOLE METAL CARBENE COMPLEXES FOR USE IN ELECTRONIC DEVICES SUCH AS OLEDS | BASF SE (DE) | 2016-06-16 | — | — | US | claimed |
| EP-3027630-A1 | LUMINESCENT DIAZA- MONOAZA- AND BENZIMIDAZOLE METAL CARBENE COMPLEXES FOR USE IN ELECTRONIC DEVICES SUCH AS OLEDS | BASF SE (DE) | 2016-06-08 | — | — | EP | claimed |
| WO-2015014944-A1 | LUMINESCENT DIAZA- MONOAZA- AND BENZIMIDAZOLE METAL CARBENE COMPLEXES FOR USE IN ELECTRONIC DEVICES SUCH AS OLEDS | BASF SE (DE) | 2015-02-05 | — | — | WO | claimed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | claimed |
| JP-4359817-B2 | — | — | 2009-11-11 | — | — | JP | claimed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | claimed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER HEALTHCARE LLC | 2006-01-26 | — | — | US | claimed |
| JP-2004537511-A | — | — | 2004-12-16 | — | — | JP | claimed |
| EP-1379507-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| EP-1379505-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160172606-A1 | LUMINESCENT DIAZA-MONOAZA-AND BENZIMIDAZOLE METAL CARBENE COMPLEXES FOR USE IN ELECTRONIC DEVICES SUCH AS OLEDS | OCIAD1, OCIAD2, OXA1L | KIF11 4442/4885 |
| US-10290817-B2 | Luminescent diaza-monoaza-and benzimidazole metal carbene complexes for use in electronic devices such as OLEDs | OCIAD1, OCIAD2, OXA1L | KIF11 4442/4885 |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BRAF, RAF1, ARAF | KIF11 2080/4885 |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | KIF11 2068/4885 |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BRAF, RAF1, ARAF | KIF11 2080/4885 |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK3 | KIF11 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.